18.71

4.58% -0.8916

Acadia Pharmaceuticals Inc (ACAD)

Overview News Price History Option Chain Financials Why ACAD Down? Discussions Forecast

Acadia Pharmaceuticals Inc stock is traded at $18.71, with a volume of 853.97K. It is down -4.58% in the last 24 hours and up +1.04% over the past month. Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Previous Close:

$19.60

Open:

$19.56

24h Volume:

853.97K

Relative Volume:

0.38

Market Cap:

$3.13B

Revenue:

$890.53M

Net Income/Loss:

$30.57M

P/E Ratio:

103.94

EPS:

0.18

Net Cash Flow:

$80.53M

1W Performance:

-3.99%

1M Performance:

+1.04%

6M Performance:

+14.32%

1Y Performance:

-22.10%

1-Day Range:

$18.47

$19.69

1-Week Range:

$18.47

$20.62

52-Week Range:

$14.15

$24.27

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name

Acadia Pharmaceuticals Inc

Sector

Healthcare (1188)

Industry

Biotechnology (679)

Phone

858-558-2871

Address

12830 EL CAMINO REAL, SAN DIEGO

Employee

620

Twitter

@acadiapharma

Next Earnings Date

2024-11-06

Latest SEC Filings

ACAD's Discussions on Twitter

Compare ACAD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACAD Acadia Pharmaceuticals Inc	18.71	3.13B	890.53M	30.57M	80.53M	0.18
VRTX Vertex Pharmaceuticals Inc	490.02	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	688.15	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	634.08	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.19	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	112.76	27.34B	3.30B	-501.07M	1.03B	-2.1146

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Deutsche Bank	Hold
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Mar-12-24	Downgrade	Mizuho	Buy → Neutral
Mar-12-24	Reiterated	Needham	Buy
Jan-30-24	Initiated	Robert W. Baird	Outperform
Jan-24-24	Upgrade	Needham	Hold → Buy
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold
Dec-13-23	Initiated	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-06-23	Upgrade	Mizuho	Neutral → Buy
Oct-17-23	Initiated	UBS	Buy
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy
Nov-04-22	Downgrade	Goldman	Neutral → Sell
Nov-01-22	Initiated	Loop Capital	Hold
Aug-08-22	Downgrade	Citigroup	Buy → Neutral
Aug-05-22	Downgrade	Citigroup	Buy → Neutral
Jun-21-22	Downgrade	Jefferies	Buy → Underperform
Jun-16-22	Upgrade	Jefferies	Hold → Buy
Mar-16-22	Upgrade	Canaccord Genuity	Hold → Buy
Feb-09-22	Upgrade	H.C. Wainwright	Neutral → Buy
Jan-05-22	Upgrade	Citigroup	Neutral → Buy
Dec-21-21	Downgrade	Guggenheim	Buy → Neutral
Nov-01-21	Upgrade	Guggenheim	Neutral → Buy
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Jun-10-21	Initiated	Berenberg	Hold
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-06-21	Downgrade	Canaccord Genuity	Buy → Hold
Apr-06-21	Downgrade	Goldman	Buy → Neutral
Apr-06-21	Downgrade	Jefferies	Buy → Hold
Apr-06-21	Downgrade	Mizuho	Buy → Neutral
Apr-05-21	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-10-21	Downgrade	BofA Securities	Buy → Neutral
Mar-09-21	Downgrade	Citigroup	Buy → Neutral
Mar-09-21	Downgrade	Guggenheim	Buy → Neutral
Mar-09-21	Reiterated	H.C. Wainwright	Buy
Mar-09-21	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-21	Downgrade	Stifel	Buy → Hold
Dec-16-20	Initiated	Mizuho	Buy
Nov-16-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Initiated	Morgan Stanley	Overweight
Jul-07-20	Upgrade	Stifel	Hold → Buy
Apr-16-20	Initiated	Jefferies	Buy
Mar-31-20	Upgrade	Goldman	Neutral → Buy
Mar-06-20	Initiated	Citigroup	Buy
Dec-16-19	Initiated	Guggenheim	Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-01-19	Initiated	RBC Capital Mkts	Outperform
Sep-13-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-10-19	Upgrade	Canaccord Genuity	Hold → Buy
Jul-23-19	Reiterated	Needham	Buy
Dec-10-18	Initiated	Canaccord Genuity	Hold
Sep-21-18	Upgrade	Piper Jaffray	Neutral → Overweight
Aug-09-18	Reiterated	Stifel	Hold
Aug-07-18	Initiated	Stifel	Hold
Aug-06-18	Downgrade	Piper Jaffray	Overweight → Neutral
Oct-06-17	Resumed	Goldman	Neutral

View All

Acadia Pharmaceuticals Inc Stock (ACAD) Latest News

09:05 AM

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study - The Bakersfield Californian

09:05 AM

Can Acadia's New Essential Tremor Drug Candidate Survive Its Clinical Trial Pause? - StockTitan

09:05 AM

Mar 02, 2025

Acadia Pharmaceuticals Ends FY2024 On Solid Footing (NASDAQ:ACAD) - Seeking Alpha

Mar 02, 2025

Mar 01, 2025

FY2025 EPS Estimates for ACAD Decreased by Cantor Fitzgerald - MarketBeat

Mar 01, 2025

Brokers Issue Forecasts for ACAD Q1 Earnings - MarketBeat

Mar 01, 2025

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Phocas Financial Corp. - MarketBeat

Mar 01, 2025

Los Angeles Capital Management LLC Grows Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Mar 01, 2025

Feb 28, 2025

Insider Selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) CFO Sells 773 Shares of Stock - MarketBeat

Feb 28, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Trading Up 6.4%Should You Buy? - MarketBeat

Feb 28, 2025